2025-02-04T17:28:51-08:00 2024-12-31 271661785 CMRosen LLC 17440 Dallas Pkwy Ste 218 Dallas TX 75287 990 2024-01-01 820864340 Cure RTD Foundation CURE 9728610415 PO Box 1228 Red Oak TX 75154 Carly Gilbert VP / Treasurer 2025-02-04 true true Chad M Rosen CPA P01071321 9728181400 2024 2025-03-06 01:10:19Z Chad Griffith PO Box 1228 Red Oak TX 75154 388162 false X curertd.org X 2017 TX To encourage, guide, and fund additional research to improve understanding, diagnosis, and treatment of Riboflavin Transporter Deficiency ("RTD"). 5 4 1 10 0 380248 366614 0 21548 291 0 380539 388162 225271 131712 0 16568 16540 0 1854 16299 6053 258138 154305 122401 233857 1097526 1331383 0 1097526 1331383 To encourage, guide, and fund additional research to improve understanding, diagnosis, and treatment of Riboflavin Transporter Deficiency ("RTD"). false false 131996 131712 Cure RTD Foundation is proud to have funded the three following research projects in advancement of the understanding and treatment of RTD:(a) $100,000 to a University of California project aiming to find all proteins with significant interactions with the RFVT2 (SLC52A2) transporter. Protein-protein interactions occur in all transporters. Outside proteins can cause up or down-regulation of the transporter function, change transporter stability, or even membrane targeting. This topic has not been investigated in RFVT2, so we have no idea what proteins interact with RFVT2. These proteins could up or down-regulated the transporter and, in many cases, can be regulated by various strategies (drugs, diet, gene therapy, etc.). Strategies targeting interacting proteins and their binding interfaces are receiving increasing attention as a therapeutic approach. The grant is complimentary to several ongoing RTD projects and could lead to direction changes in those projects if significant discoveries are found. This project also has the potential to lead to substantial NIH funding for future RTD projects.(b) $23,715 to The Jackson Laboratory. Riboflavin transporter deficiency (RTD) is a rare neurodegenerative genetic disorder with onset most often in early childhood. RTD effects motor and sensory neurons causing loss of the ability to hear, see, move and breath. RTD is caused by mutations in the SLC52A2 and SLC52A3 genes. C57BL/6J-Slc52a2em6 (L341L,L344P) Lutzy/Lutzy (JR#034144) homozygous mice are viable and lack any phenotypes. Standard chow the mice are fed has a high level of riboflavin, and it has been hypothesized that the high levels of riboflavin may be alleviating any phenotypes caused by the mutation in the SLC52A2 gene. The goal of this project is to determine if decreasing the amount of riboflavin in the chow will induce a phenotype in C57BL/6J-Slc52a2em6(L341L,L344P) Lutzy/Lutzy (JR#034144) homozygous mice.(c) $7,997 to an AMC Hospital Amsterdam to fund the Metabolomics Labs for Project 23P0066. 131996 true true false false false false false false false false false false false false false false false false false false false true false false false false false true false false false false false false false false false false false false false false false false false false false true 0 0 false 1 true false false false false false false false 0 false false false false false false false X 5 4 false false false false false false false true false false false true true true true true true false true false X X Carly Gilbert 9728610415 PO Box 1228 Red Oak TX 75154 Carly Gilbert VP / Treasurer 8.00 0.00 X X 15000 0 0 Clayton Greene Secretary 3.00 0.00 X X 0 0 0 Clara O'Rourke Director 8.00 0.00 X 0 0 0 Keith Massey Director 30.00 0.00 X 0 0 0 Chad Griffith President 8.00 0.00 X X 0 0 0 15000 0 false false false 0 15 366599 366614 0 21548 21548 0 0 0 0 0 0 0 0 388162 21548 123715 123715 0 7997 7997 0 13513 135 12702 676 0 0 0 0 3027 30 2846 151 0 0 0 0 0 0 2962 9 2907 46 1074 974 100 1336 110 345 881 681 681 0 0 0 0 0 0 0 0 0 0 154305 131996 20455 1854 1097526 518191 813192 0 0 0 0 0 0 0 0 0 0 0 0 0 1097526 1331383 0 0 X 1097526 1331383 1097526 1331383 1097526 1331383 233857 X false false false X 257468 337166 378086 380248 366614 1719582 0 0 257468 337166 378086 380248 366614 1719582 57943 1661639 282 348 378 291 21548 22847 0 0 1742429 1011 0.95360 0.96560 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED Europe Medical research 7997 Wire Trfr 1 false false false false false false Part II, Line 1 - Method of Accounting The expenditures are reported using the cash basis of accounting. true The Jackson Laboratory 600 Main St Bar Harbor ME 04609 010211513 501(c)(3) 23715 0 Medical research University of California 821 Health Science Rd Rm C348 Irvine CA 92697 943067788 Gov - Univ of CA 100000 0 Medical research 2 0 Grantmaker's Description of How Grants are Used Periodic reports, along with a detailed final report and analysis with findings, are required for each grant to account for how the grant funds are used. Future grant awards are contingent upon receipt of such reports to ensure that valuable resources are not wasted on research that is not beneficial. Form 990, Part VI, Section A, Line 8b There are no such committees. Form 990, Part VI, Section B, Line 11b A copy of this return was provided to the Organization's Directors for review and approval before filing. Form 990, Part VI, Section B, Line 12c Any director, principal officer, or member of a committee with governing boarddelegated powers, who has a direct or indirect financial interest, as defined below, is an interested person. In connection with any actual or possible conflict of interest, an interested person must disclose the existence of the financial interest and be given the opportunity to disclose all material facts to the directors and members of committees with governing board delegated powers considering the proposedtransaction or arrangement (and annual disclosure statements must be signed annually, and periodic reviews shall be conducted). After any discussion with the interested person, he/she shall leave the governing board or committee meeting while the determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. Conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. In this case, the interesed person may make a presentation at the governing board or committee meeting, but after the presentation, he/she shall leave the meeting during the discussion of, and the vote on, the transaction or arrangement involving the possible conflict of interest. The chairperson of the governing board or committee shall, if appropriate, appoint a disinterested person or committee to investigate alternatives to the proposed transaction or arrangement. After exercising due diligence, the governing board or committee shall determine whether the Organization can obtain, with reasonable efforts, a more advantageous transaction or arrangement from a person or entity that would not give rise to a conflict of interest. If a more advantageous transaction or arrangement isnt reasonably possible under circumstances not producing a conflict of interest, the governing board or committee shall determine by a majority vote of the disinterested directors whether the transaction or arrangement is in the Organizations best interest, for its own benefit, and whether it is fair and reasonable. In conformity with the above determination, it shall make its decision as to whether to enter into the transaction or arrangement. Form 990, Part VI, Section B, Line 15b The Organization's top management official was not compensated during the year, but compensation of the VP / Treasurer was determined and approved by a majority of independent Directors after considering comparability data reported by National Council of Nonprofits and GuideStar, as documented in the minutes in 2022. Form 990, Part VI, Section C, Line 19 These documents are available on the Organization's website and upon request.